NDAINTRAVENOUSINJECTABLE
Approved
Oct 2013
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Clinical Trials
1
Data completeness
6/8 — Strong
VIZAMYL (flutemetamol f-18) by GE HealthCare is radiopharmaceutical activity [moa]. Approved for radioactive diagnostic agent [epc]. First approved in 2013.
Drug data last refreshed 8h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VIZAMYL (Flutemetamol F-18) is a radioactive diagnostic agent administered intravenously for positron emission tomography (PET) imaging. It is used to detect amyloid pathology in the brain, primarily in patients with cognitive impairment to support Alzheimer's disease diagnosis. The drug works by binding to amyloid-beta plaques in neural tissue, allowing visualization via PET imaging.
LOE Approaching2.1 years to LOE
Product approaching loss of exclusivity in ~2.2 years; commercial teams should expect declining market share and shifting focus to competitive differentiation or pipeline transition.
Mechanism of Action
Radiopharmaceutical Activity
Pharmacologic Class:
Radioactive Diagnostic Agent
Indications (1)
Clinical Trials (1)
A Study to Evaluate the Effectiveness of VIZAMYL™ Reader Training Programme in Europe
Started Dec 2018
227 enrolled
Cognitive Impairment
Why This Matters for Your Career
Worked on VIZAMYL at GE HealthCare? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.